Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Supreme Court Rules That Human Genes Can’t Be Patented

Published: Friday, June 14, 2013
Last Updated: Friday, June 14, 2013
Bookmark and Share
Most agree that the ruling reduces barriers to genetic testing and enables scientists to further genetic research and share data aimed ultimately at preventing and curing disease.

The scientific community at UC San Francisco is reacting positively to the Supreme Court’s unanimous ruling on Thursday that human genes cannot be patented.

“This is great news for patient care,” says Beth Crawford, MS, a genetic counselor and director of genetic counseling for the Cancer Risk Program at the UCSF Helen Diller Family Comprehensive Cancer Center. “It will provide patients with greater access to genetic testing and will decrease the cost over time for the tests. Across the board, genetic medicine will move forward to advance scientific and clinical research.”

Adds Julie Mak, MS, also a genetic counselor for the Cancer Risk Program, "Our community is enormously excited to learn that the Supreme Court of the United States has ruled against the patenting of human genes. We agree that this is appropriate, as genes are naturally occurring and not the creation of any individual or company."

Until now, if a woman in the United States wanted to get tested to see whether she carried a potentially deadly mutation for two breast cancer genes – BRCA1 and BRCA2 – she had to go through a company that had found the precise location of the genes and patented its discovery.

The company, Utah-based Myriad Genetics, Inc., was sued over its claim of patents relating to BRCA1 and BRCA2, whose mutations are linked to increased hereditary risk for breast and ovarian cancer.

Myriad Genetics angered many in the genetic research community by guarding tightly the results of the thousands of tests that have been performed since Myriad launched the BRACAnalysis test in 1996, and with those, critical data on which mutations are significant for people of diverse backgrounds. Those critics include UCSF geneticist Robert Nussbaum, MD, who argued that the genetic information should be in the public domain to help advance scientific discovery.

Nussbaum, chief of the Division of Genomic Medicine at UCSF, started a grass-roots project,Sharing Clinical Reports, to make the vast amount of data gleaned from Myriad available to the research community.

“My real focus is on delivering medical care,” Nussbaum, who was in clinic Thursday and unavailable to comment, told KQED’s “On the Media” in an interview last month. “Suppose every radiology department in the country took X-rays, interpreted their results and kept it private to themselves. … How much progress would have been made in interpreting CAT scans or MRI scans under that circumstance? I see that as very analogous.”

The Supreme Court on Thursday ruled that “naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated,” Justice Clarence Thomas wrote in the majority opinion.

The ruling is seen as somewhat of a split decision since all nine justices said while the naturally occurring, isolated biological material itself is not patentable, a synthetic version of the gene material may be patented.

The genes at issue – BRCA1 and BRCA2 – recently made national headlines when actress Angelina Jolie got a double mastectomy after testing for mutations and discovering that she had an elevated risk of developing breast and ovarian cancer. But the test – which can cost about $3,000 – was too expensive for many women to take.

Already on Thursday, competitors to Myriad Genetics were getting ready to offer the tests, which is expected to drive down pricing.

"The decision represents a victory for all those eagerly awaiting more individualized, gene-based approaches to medical care,” said Francis Collins, MD, PhD, director of the National Institutes of Health (NIH). "The right to control exclusively the use of a patient’s genes could have made it more difficult to access new tests and treatments that rely on novel technologies that can quickly determine the sequence of any of the estimated 20,000 genes in the human genome. Such approaches form the cornerstone of the rapidly emerging field of personalized medicine, in which diagnostic, therapeutic, and preventive strategies can be tailored to each person’s unique genetic makeup."

Continuing Dialogue on Commercialization of Genetic Material

Daniel Dohan, PhD, associate professor of Health Policy and Social Medicine in the Philip R. Lee Institute for Health Policy Studies (IHPS), says the ruling returns sound reasoning on patenting genetic material.

 “The law in this area has seemed more and more untenable for a number of years and the court’s ruling in this case returns the issue to a more reasoned discussion. Genes have been around for billions of years; the notion that we can patent them was incongruous."

From a policy standpoint, Dohan said the ruling leaves open questions about whether it will spark useful market competition.

“The whole point is to get discoveries out of the lab and to conduct that translational research that will benefit patients,” Dohan said.

He questioned whether over the long term, companies will want to invest will in basic research on the genetic underpinnings of disease. If incentives on earning patent income are removed or restricted, it may have a chilling effect on industry-academic partnerships.

Today’s ruling, he said, is extending the national dialogue on the commercialization of genetic material.

“The NIH budget is getting smaller and increasingly research institutions are partnering with industry. That's where this more complex issue comes in with questions about funding basic science.”

As co-lead of the UCSF/UC Hastings Consortium on Law, Science, and Health Policy, which is building a variety of relationships between the two schools, Dohan will moderate a panel discussion on the Supreme Court ruling on June 27 at UCSF Mission Bay. 

“Over the short- to medium-term it will make some of these genetic tests more affordable and that’s good for people who are underserved,” Dohan said. “And it’s a huge win for the research community interested in exploring these genes and has felt squelched around patent issues on naturally occurring DNA.”

Expanding Patient Access to Genetic Testing

Crawford, one of the nation’s first cancer genetic counselors whose work began at UCSF in 1996, says the ruling also means that a lot more genetic panels and next-generation sequencing will become available so that clinicians and patients can make more informed decisions about treatment and prevention of cancer.

"This ruling will give patients more access to complete BCRA1 and BCRA2 genetic testing at a lower cost," she said. 

The improved access will affect patients who are appropriate candidates for BCRA1 and BCRA2 gene testing and have not yet been tested. It also affects patients who were tested in the past but had incomplete testing. Specifically, because testing was availalble through a single laboratory at a high cost, many patients have not had testing for large deletions or duplications, also called "rearrangements" in these BCRA1 and BCRA2.

"We recommend that patients review their test reports to see if their testing included both sequencing and full gene rearrangement testing or call their genetic counselor," Crawford said.

Crawford, who received the UCSF Milton and Helen Pearl Award for Excellence in May, began working with nationally renowned breast cancer surgeon Laura Essermann, MD, MBA, 17 years ago at UCSF, one of only a few places around the country at the time that offered genetic counseling as part of its clinical services.

Crawford explains that there could be an impact on I-SPY because BCRA1 and BCRA2 testing will be more accessible at lower cost and gene test status could impact what types of treatment a patient receives. While this is an enormous breakthrough in genetic testing for hereditary breast and ovarian cancer, as well as other conditions, there is much work left to do.

“Data will be freed up on variants of BCRA1 and 2, and now we could use that information for research and clinical care to learn more about whether those variants are disease causing.”

Making Data Available to Improve Health

Nussbaum told KQED last month that Myriad took the genes out of the public domain because they thought the information was being misused for clinical purposes. “I find that a very difficult explanation because the information is being not misused, but used all the time in clinics to make very serious decisions about medical care.”

One of the major advantages to freeing up the data is the ability for patients to get a second opinion on a variant found on BRCA1 or BRCA2 genes and to share that information across the scientific community to learn from it. “The whole point is to have a community of molecular geneticists analyzing this data and deciding – almost as a crowd-sourced curation – what do we think these variants mean,” he said.

Nussbaum said the real issue is about saving lives and sharing data to improve health.

“I don’t like to sit across from a patient and say to them, ‘Well, we tested your gene. We found this variant. I don’t know what it means,’” he said. “And now I’ve introduced a huge amount of worry into this patient’s mind without being able to satisfy it one way or another. I can’t tell them what it means. It happens to me pretty much every week. That’s not the way I want to practice medicine.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Immune System Implicated in Gastroschisis
UCSF researchers show that the immune system is implicated in gastroschisis. The findings could lead to improved treatments for the belly birth defect.
Tuesday, May 17, 2016
Cytokine Triggers Immune Response at Expense of Blood Renewal
Research highlights promise of Anti-IL-1 drugs to treat chronic inflammatory disease.
Tuesday, April 26, 2016
Tense Tumours Lead to Poorer Prognosis
UCSF researchers have discovered that the chances of survival for patients with pancreatic adenocarcinoma (PDAC) — the most common type of pancreatic cancer — may depend in part on how tense their tumors are.
Tuesday, April 19, 2016
Gene Behind Rare Childhood Syndrome Identified
Online activism by one patient’s mother spurred research collaboration which led to the identification of a new genetic syndrome.
Friday, April 15, 2016
UCSF Immunologist to Head New Parker Institute for Cancer Immunotherapy
Renowned UC San Francisco immunologist Jeffrey Bluestone, PhD, has been named president and CEO of the Parker Institute for Cancer Immunotherapy, a national initiative launched with a $250 million grant from The Parker Foundation.
Thursday, April 14, 2016
How The Bat Got Its Wings
Finding may provide clues to human limb development and malformations.
Wednesday, March 30, 2016
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Wednesday, February 03, 2016
MedImmune, UCSF Launch Collaboration
Top scientists partner to research the progression and biology of RIA diseases.
Thursday, January 14, 2016
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Thursday, August 20, 2015
How Early Childhood Vaccination Reduces Leukemia Risk
Chronic infections push ‘pre-leukemia’ cells, common in newborns, into malignancy.
Thursday, May 21, 2015
Blood Test Trumps Accuracy of Standard Screening in Detecting Down Syndrome in Early Pregnancy
A blood test undertaken between 10 to 14 weeks of pregnancy may be more effective in diagnosing Down syndrome and two other less common chromosomal abnormalities than standard non-invasive screening techniques.
Thursday, April 02, 2015
Developing a Noninvasive Test for Endometriosis
UCSF researchers identify patterns of genetic activity that could help in early detection of disorder.
Monday, November 24, 2014
Environmental Carcinogens Leave Distinctive Genetic Imprints in Tumors
Chemically induced tumors bear ‘smoking gun’ traces that sharply differentiate them from genetically engineered cancers.
Thursday, November 06, 2014
Human Cancer Prognosis Is Related to Newly Identified Immune Cell
A rare population of tumor-associated “good” cells slows cancer.
Monday, October 20, 2014
Chromosome Therapy to Correct a Severe Chromosome Defect
Induced pluripotent stem cell reprogramming offers potential to correct abnormal chromosomes.
Tuesday, January 14, 2014
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
New NIH-EPA Research Centers to Study Environmental Health Disparities
Scientists will partner with community organizations to study these concerns and develop culturally appropriate ways to reduce exposure to harmful environmental conditions.
Structure of Essential Digestive Enzyme Uncovered
Using a powerful combination of techniques from biophysics to mathematics, researchers have revealed new insights into the mechanism of a liver enzyme that is critical for human health.
Air Pollution Linked to Heart Disease
10-year project revealed air pollutants accelerate plaque build-up in arteries to the heart.
Getting a Better Look at How HIV Infects and Takes Over its Host Cells
A new approach, developed by a team of researchers led by The Rockefeller University and The Aaron Diamond AIDS Research Center (ADARC), offers an unprecedented view of how a virus infects and appropriates a host cell, step by step.
Following Tricky Triclosan
Antibacterial product flows through streams, crops.
Vitamin A May Help Improve Pancreatic Cancer Chemotherapy
The addition of high doses of a form of vitamin A could help make chemotherapy more successful in treating pancreatic cancer, according to an early study by Queen Mary University of London (QMUL).
Poverty Marks a Gene, Predicting Depression
New study of high-risk teens reveals a biological pathway for depression.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!